David T Levy1, Ron Borland2, Andrea C Villanti3, Raymond Niaura3, Zhe Yuan1, Yian Zhang1, Rafael Meza4, Theodore R Holford5, Geoffrey T Fong6,7,8, K Michael Cummings9, David B Abrams1,3,10. 1. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC. 2. VicHealth Centre for Tobacco Control, The Cancer Council Victoria, Melbourne, Victoria, Australia. 3. Schroeder Institute for Tobacco Research and Policy Studies at Truth Initiative, Washington DC. 4. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI. 5. Department of Biostatistics, Yale University, New Haven, CT. 6. Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada. 7. School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada. 8. Ontario Institute for Cancer Research, Toronto, Ontario, Canada. 9. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC. 10. Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Abstract
INTRODUCTION: The public health impact of vaporized nicotine products (VNPs) such as e-cigarettes is unknown at this time. VNP uptake may encourage or deflect progression to cigarette smoking in those who would not have otherwise smoked, thereby undermining or accelerating reductions in smoking prevalence seen in recent years. METHODS: The public health impact of VNP use are modeled in terms of how it alters smoking patterns among those who would have otherwise smoked cigarettes and among those who would not have otherwise smoked cigarettes in the absence of VNPs. The model incorporates transitions from trial to established VNP use, transitions to exclusive VNP and dual use, and the effects of cessation at later ages. Public health impact on deaths and life years lost is estimated for a recent birth cohort incorporating evidence-informed parameter estimates. RESULTS: Based on current use patterns and conservative assumptions, we project a reduction of 21% in smoking-attributable deaths and of 20% in life years lost as a result of VNP use by the 1997 US birth cohort compared to a scenario without VNPs. In sensitivity analysis, health gains from VNP use are especially sensitive to VNP risks and VNP use rates among those likely to smoke cigarettes. CONCLUSIONS: Under most plausible scenarios, VNP use generally has a positive public health impact. However, very high VNP use rates could result in net harms. More accurate projections of VNP impacts will require better longitudinal measures of transitions into and out of VNP, cigarette and dual use. IMPLICATIONS: Previous models of VNP use do not incorporate whether youth and young adults initiating VNP would have been likely to have been a smoker in the absence of VNPs. This study provides a decision-theoretic model of VNP use in a young cohort that incorporates tendencies toward smoking and shows that, under most plausible scenarios, VNP use yields public health gains. The model makes explicit the type of surveillance information needed to better estimate the effect of new products and thereby inform public policy.
INTRODUCTION: The public health impact of vaporized nicotine products (VNPs) such as e-cigarettes is unknown at this time. VNP uptake may encourage or deflect progression to cigarette smoking in those who would not have otherwise smoked, thereby undermining or accelerating reductions in smoking prevalence seen in recent years. METHODS: The public health impact of VNP use are modeled in terms of how it alters smoking patterns among those who would have otherwise smoked cigarettes and among those who would not have otherwise smoked cigarettes in the absence of VNPs. The model incorporates transitions from trial to established VNP use, transitions to exclusive VNP and dual use, and the effects of cessation at later ages. Public health impact on deaths and life years lost is estimated for a recent birth cohort incorporating evidence-informed parameter estimates. RESULTS: Based on current use patterns and conservative assumptions, we project a reduction of 21% in smoking-attributable deaths and of 20% in life years lost as a result of VNP use by the 1997 US birth cohort compared to a scenario without VNPs. In sensitivity analysis, health gains from VNP use are especially sensitive to VNP risks and VNP use rates among those likely to smoke cigarettes. CONCLUSIONS: Under most plausible scenarios, VNP use generally has a positive public health impact. However, very high VNP use rates could result in net harms. More accurate projections of VNP impacts will require better longitudinal measures of transitions into and out of VNP, cigarette and dual use. IMPLICATIONS: Previous models of VNP use do not incorporate whether youth and young adults initiating VNP would have been likely to have been a smoker in the absence of VNPs. This study provides a decision-theoretic model of VNP use in a young cohort that incorporates tendencies toward smoking and shows that, under most plausible scenarios, VNP use yields public health gains. The model makes explicit the type of surveillance information needed to better estimate the effect of new products and thereby inform public policy.
Authors: Timea R Partos; Ron Borland; James F Thrasher; Lin Li; Hua-Hie Yong; Richard J O'Connor; Mohammad Siahpush Journal: Addict Behav Date: 2014-04-12 Impact factor: 3.913
Authors: Maciej Lukasz Goniewicz; Jakub Knysak; Michal Gawron; Leon Kosmider; Andrzej Sobczak; Jolanta Kurek; Adam Prokopowicz; Magdalena Jablonska-Czapla; Czeslawa Rosik-Dulewska; Christopher Havel; Peyton Jacob; Neal Benowitz Journal: Tob Control Date: 2013-03-06 Impact factor: 7.552
Authors: Israel T Agaku; Brian A King; Corinne G Husten; Rebecca Bunnell; Bridget K Ambrose; S Sean Hu; Enver Holder-Hayes; Hannah R Day Journal: MMWR Morb Mortal Wkly Rep Date: 2014-06-27 Impact factor: 17.586
Authors: David T Levy; Ron Borland; Geoffrey T Fong; Andrea C Villanti; Raymond Niaura; Rafael Meza; Theodore R Holford; K Michael Cummings; David B Abrams Journal: Nicotine Tob Res Date: 2016-10-06 Impact factor: 4.244
Authors: David B Abrams; Allison M Glasser; Andrea C Villanti; Jennifer L Pearson; Shyanika Rose; Raymond S Niaura Journal: Prev Med Date: 2018-06-23 Impact factor: 4.018
Authors: Kelly C Young-Wolff; Daniella Klebaner; Bruce Folck; Andy S L Tan; Renee Fogelberg; Varada Sarovar; Judith J Prochaska Journal: Prev Med Date: 2018-01-31 Impact factor: 4.018
Authors: Samir Soneji; Jessica L Barrington-Trimis; Thomas A Wills; Adam M Leventhal; Jennifer B Unger; Laura A Gibson; JaeWon Yang; Brian A Primack; Judy A Andrews; Richard A Miech; Tory R Spindle; Danielle M Dick; Thomas Eissenberg; Robert C Hornik; Rui Dang; James D Sargent Journal: JAMA Pediatr Date: 2017-08-01 Impact factor: 16.193
Authors: Ron Borland; Krista Murray; Shannon Gravely; Geoffrey T Fong; Mary E Thompson; Ann McNeill; Richard J O'Connor; Maciej L Goniewicz; Hua-Hie Yong; David T Levy; Bryan W Heckman; K Michael Cummings Journal: Addiction Date: 2019-04-02 Impact factor: 6.526
Authors: Kar-Hai Chu; Ariel Shensa; Jason B Colditz; Jaime E Sidani; Beth L Hoffman; David Sinclair; Mary G Krauland; Brian A Primack Journal: Health Educ Behav Date: 2020-02-24